Previously, our study provides the evidence for the strong anti-tumor effects and targeting capability of NK-exos in HCC, at least in part, by novel regulatory mechanisms associated with caspase pathway-dependent apoptosis and the serine/threonine kinase pathway-mediated cell proliferation [56]. The gene discussed is MARK2; the disease is hepatocellular carcinoma.